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Abstract
Background: Although the prolonged use of rapamycin may cause unwanted side effects such as hyperlipidemia,
the underlying mechanism remains unknown. Prox1 is a transcription factor responsible for the development of
several tissues including lymphatics and liver. There is growing evidences that Prox1 participates in metabolism in
addition to embryogenesis. However, whether Prox1 is directly related to lipid metabolism is currently unknown.
Methods: HepG2 human hepatoma cells were treatedwith rapamycin and total lipidswere analyzed by thin layer
chromatography. The effect of rapamycin on the expression of Prox1was determined bywestern blotting. To investigate the role
of Prox1 in triglycerides regulation, siRNA and overexpression systemwere employed. Rapamycinwas injected intomice for
2weeks and total lipids and proteins in liver weremeasured by thin layer chromatography andwestern blot analysis, respectively.
Results: Rapamycin up-regulated the amount of triglyceride and down-regulated the expression of Prox1 in HepG2 cells by
reducing protein half-life but did not affect its transcript. The loss-of-function of Prox1was coincidentwith the increase of
triglycerides in HepG2 cells treatedwith rapamycin. The up-regulation of triglycerides by rapamycin in HepG2 cells reverted to
normal levels by the compensation of Prox1 using the overexpression system. Rapamycin also down-regulated Prox1 expression
but increased triglycerides inmouse liver.
Conclusion: This study suggests that rapamycin can increase the amount of triglycerides by down-regulating Prox1 expression in
hepatocytes, whichmeans that themammalian target of rapamycin (mTOR) signaling is important for the regulation of
triglycerides bymaintaining Prox1 expression.
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Background
Prospero-related homeobox 1 (Prox1) is a transcription
factor responsible for the development of several tissues,
such as lymphatics and liver [1–3]. Prox1 haploinsuf-
ficient mice show lymphatic vascular defects leading
to adult-onset obesity through the enhancement of
adipogenesis and increased fat storage in lymphatic-rich
regions. Prox1 knock-out mouse embryos lack lymphatic
systems and perish at day 14.5 of embryogenesis [4]. Prox1
is also known to regulate the activity of a specific subset of
nuclear receptors including hepatocyte nuclear factor 4a
(HNF4a, NR2A1) and liver receptor homolog-1 (LRH-1,
NR5A2), which suggests that Prox1 may play a key role in
the regulation of metabolism in the liver [5–7]. However,
whether Prox1 directly participates in the regulation of
lipid metabolism is currently unknown.
Rapamycin, also known as sirolimus, achieves its
unique effects by binding to the mammalian target of
rapamycin (mTOR), also known as FKBP12 rapamycin
associated protein (FRAP) or rapamycin and FKBP12
target (RAFT). mTOR is a kind of serine-threonine
kinase that belongs to the phosphatidylinositol (PI)
kinase-related protein kinase family [8, 9]. It regulates
cell growth and proliferation through translational control
of several proteins such as cyclin dependent kinase inhibi-
tor p27kip1, retinoblastoma protein, cyclin D1, c-myc and
STAT 3 [10]. mTOR can be activated by several stimuli
such as growth factors and nutrients through receptor
tyrosine kinase (RTK), phosphatidyl inositol 3 kinase
(PI3K), and Akt/PKB signaling cascade [11]. mTOR elicits
its effect by binding to the cytosolic immunophilin
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FKBP12 (FK506 binding protein, 12kd) [12]. Due to its
immunosuppressive properties, rapamycin has been used
extensively in transplantation to prevent organ rejection
[8, 13, 14]. Recently, clinical application of rapamycin has
expanded to cancer therapy [15] as well as preventing
occlusion of coronary arteries after stent placement [16].
In spite of rapamycin’s broad clinical application, it has
been reported that prolonged use of rapamycin is associ-
ated with serious adverse effects, including hyperlipidemia
[17–19]. Actually, rapamycin-associated dyslipidemia has
been reported in 45 % of liver transplant patients [20] and
in about 40 % of renal transplant patients [21]. These
results suggest that, physiologically, mTOR signaling may
play a significant role in lipid homeostasis.
In this study, we found that rapamycin increased the
amount of triglycerides and down-regulated Prox1
expression in hepatocytes, which means that mTOR
signaling is important for maintaining triglycerides as
well as Prox1 expression. To the best of our knowledge,
this study is the first report showing the down-
regulation of Prox1 by the inhibition of mTOR signal
and suggests that triglycerides are up-regulated by
rapamycin through the down-regulation of Prox1.
Results
Rapamycin increases triglycerides in HepG2 cells
To investigate the physiological effect of rapamycin on
hepatocytes, we first looked at the proliferation of
HepG2 cells treated with rapamycin (RAPA). Compared
with cells not treated with any drug (Mock) or treated
with vehicle (DMSO) alone, rapamycin did not affect
the proliferation of HepG2 cells (Fig. 1a). We then
measured the amount of triglycerides in HepG2 cells
by thin layer chromatography (TLC) and found that
rapamycin increased the amount of triglycerides in
HepG2 cells (Fig. 1b). In comparison, the quantity of
intracellular cholesterol was constant across samples,
but the relative triglycerides increased significantly in
quantity in rapamycin-treated cells (Fig. 1c). These
results indicate that rapamycin augments triglycerides in
HepG2 cells although it does not affect liver cell
proliferation.
Rapamycin down-regulates Prox1 in HepG2 cells by
decreasing protein stability
Next we focused on the expression of Prox1 in HepG2
cells treated with rapamycin. First, we treated HepG2
cells with various concentrations of rapamycin from 1 to
50 nM. After 48 h, we analyzed Prox1 and found that its
expression was decreased by rapamycin (Fig. 2a). The
phosphorylated form of mTOR was detected to verify
the inhibitory effect of rapamycin. Then we investigated
the change in Prox1 expression induced by rapamycin
over time. Although expression of Prox1 gene in HepG2
cells was not affected by the vehicle (DMSO), it was
down-regulated by rapamycin after 24 h and decreased
at 48 h (Fig. 2b). We then investigated whether the
down-regulation of Prox1 expression by rapamycin is
occurred by affecting transcript or protein. We first
checked Prox1 mRNA in HepG2 cells and found that
Fig. 1 Rapamycin increases the amount of triglycerides in HepG2 cells but does not affect cellular proliferation. a HepG2 cells were cultured in
low-serum media (1 % FBS) with or without rapamycin (RAPA, 10 nM). After 48 h, cell proliferation was measured by WST-1 assay. Mock: untreated
control group. b HepG2 cells treated with or without rapamycin were harvest after 48 h and intracellular triglycerides was measured by thin layer
chromatography (TLC). TG: triglycerides, Cho: cholesterol. c Relative triglycerides were analyzed using the Image J program (p < 0.05)
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rapamycin does not affect the expression of Prox1
mRNA (Fig. 2c). Then we employed cycloheximide to
examine the half-life of the protein. Prox1 protein was
expressed well at 6 h after cycloheximide treatment in
DMSO-treated HepG2 cells, but it was decreased after
4 h in rapamycin-treated cells (Fig. 2d). These data
demonstrate that rapamycin down-regulates Prox1
expression and affects protein stability but not mRNA
expression.
Prox1 is a critical factor for the regulation of triglycerides
in HepG2 cells
To verify the role of Prox1 in the regulation of triglycer-
ides, we employed siRNA against Prox1 mRNA (siProx1).
siProx1 showed dramatic knock-down effect at 48 h after
delivery, and the lipid analysis was performed at 4 days
after siRNA. Prox1 expression was reduced by siProx1
as well as by rapamycin, and was almost negligible
with rapamycin combined with siProx1 (Fig. 3a). The
Fig. 2 Rapamycin affects Prox1 protein but not its transcript. a HepG2 cells were treated with various concentrations of rapamycin from 1
to 50 nM. After 48 h, cells were harvested and analyzed by western blot. Phosphorylated mTOR (p-mTOR) was detected to confirm the
inhibitory effect of rapamycin. mTOR and β-actin were measured as quantitative controls. (*: p < 0.05, ***: p < 0.001). b The expression of
Prox1 in HepG2 cells was down-regulated by rapamycin after 24 h and decreased at 48 h. c Total RNAs were prepared from HepG2 cells incubated
with or without rapamycin and analyzed by semi-quantitative RT-PCR (right panel) and real-time quantitative RT-PCR (left panel). d HepG2 cells were
treated with or without rapamycin for 12 h and exposed to additional incubation with cycloheximide. The expression of Prox1 was maintained at 6 h
after cycloheximide treatment in DMSO-treated HepG2 cells, but it decreased after 4 h in rapamycin-treated cells
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phosphorylated form of mTOR disappeared following the
treatment with the inhibitor. After confirming the
decrease of Prox1 expression by siRNA, we looked at the
variation in triglycerides. Interestingly, the amount of
triglycerides in HepG2 cells was increased by siProx1 (siP)
as well as by rapamycin and was much higher with
rapamycin combined with siProx1 (Fig. 3b). These results
indicate that the amount of triglycerides in HepG2 cells is
increased by the down-regulation of Prox1, which is simi-
lar to the result of rapamycin treatment. In comparison
with intracellular cholesterol, the relative triglycerides
were also significantly increased by siProx1 as well as by
rapamycin (Fig. 3c). We next determined whether
rapamycin-induced up-regulation of triglycerides was
diminished by the compensation of Prox1 in HepG2 cells.
We employed a Prox1 over-expression system and found
that the down-regulation of Prox1 expression by rapamycin
was reversed (Fig. 3d). Moreover, Prox1 over-expression
down-regulated the increase of triglycerides induced by
rapamycin but did not affect triglycerides in HepG2 cells in
the absence of rapamycin (Fig. 3e and f ). These data
indicate that Prox1 plays a key role in the regulation
Fig. 3 Prox1 plays a crucial role in the regulation of triglycerides in HepG2 cells. a HepG2 cells were transfected with siRNA against Prox1 mRNA
(siProx1) or control siRNA (siCTR). After 48 h, cells were treated with or without rapamycin for additional 48 h. Phosphorylated mTOR (p-mTOR) was
detected to confirm the inhibitory effect of rapamycin. mTOR and β-actin were measured as quantitative controls. b Total lipids were harvested from
HepG2 cells manipulated as (a). siC and siP indicate control siRNA and siProx1, respectively. TG: triglycerides, Cho: cholesterol. c The amount of relative
triglycerides compared with cholesterol was also increased by siProx1 as well as rapamycin and was statistically significant (p < 0.05). d HepG2 cells
were transfected with a plasmid expressing human Prox1 or an empty plasmid. After 24 h, cells were treated with or without rapamycin for additional
48 h. R and D indicate rapamycin and DMSO, respectively. e TLC analysis using (d) samples. TG: triglycerides, Cho: cholesterol. f The relative analysis
shows that the increase in triglycerides caused by rapamycin was significantly down-regulated by Prox1 over-expression (p < 0.05)
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of triglycerides and that the up-regulation of Prox1
may helpful for regulating triglycerides in hepatocytes
treated with rapamycin.
Rapamycin increases triglycerides but decreases Prox1 in
mouse liver
To understand the in vivo effect of rapamycin, we set out
to evaluate the up-regulation of triglycerides and the
down-regulation of Prox1 by daily intraperitoneal injec-
tions of rapamycin (4 mg/kg) into mouse. After 2 weeks,
mice were sacrificed and total lipids and proteins were
extracted from liver. Congruent with the results of the ex
vivo experiment using HepG2 cells, rapamycin increased
the amount of triglycerides but did not affect
cholesterol in mouse liver (Fig. 4a). In comparison
with cholesterol, relative triglycerides were signifi-
cantly increased in rapamycin-treated liver cells
(Fig. 4b). We next investigated the effect of rapamy-
cin on the expression of Prox1 and found that rapa-
mycin decreased the expression of Prox1 in mouse
liver (Fig. 4c and d). The phosphorylated form of
mTOR was detected for verifying the inhibitory effect
of rapamycin, and mTOR or β-actin was detected as
a quantitative control. These results indicate that
rapamycin increases the amount of triglycerides while
down-regulating the expression of Prox1 in mouse
liver.
Discussion
Rapamycin, an immunosuppressant, has an intracellular
target, mTOR (FKBP12) and has been used to prevent
graft rejection [8, 13, 14]. Although clinical application
of rapamycin has been used successfully in transplant-
ation, adverse effects can be provoked by its prolonged
use. Hyperlipidemia including hypertriglyceridemia is
one of the side effects of rapamycin [17–19]. Recent
studies have reported that rapamycin can inhibit the
transactivation of several transcription factors such as per-
oxisome proliferator-associated receptor-gamma (PPARγ)
and CCAAT-enhancer-binding proteins (C/EBP), which
play key roles in lipid metabolism [22] and it can change
the expression of key enzymes required for fatty acid
uptake and triglyceride synthesis in adipose tissue [23]. In
spite of many trials to better understand the hyperlipid-
emia caused by rapamycin, the underlying mechanism
remains unknown.
Prox1 is a transcription factor responsible for the
development of several tissues including lymphatics and
liver [3, 24]. Previous studies have mainly focused on the
Fig. 4 Prox1 in mouse liver is down-regulated by rapamycin. a Rapamycin or vehicle was injected daily into mouse (n = 5/group) intraperitoneally
for 2 weeks. Total lipids and proteins were extracted from liver and used for TLC and western blot analysis, respectively. TG: triglycerides, Cho: cholesterol.
b Relative triglycerides compared to cholesterol shows a statistically significant increase in quantity in rapamycin-treated tissues (p< 0.05). c Western blot
analysis shows that rapamycin down-regulated prox1 expression. d The expression of prox1 was analyzed by comparing with β-actin, which shows a
statistically significant down-regulation of prox1 expression by rapamycin (p < 0.01)
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function of Prox1 in embryogenesis [1–3]. However,
Prox1 is also known to regulate the activity of several
nuclear receptors such as HNF4a (NR2A1) and LRH-1
(NR5A2), which indicates that Prox1 may play a role in
the regulation of metabolism in the liver [5, 6]. Indeed,
there is growing evidences that Prox1 participates in me-
tabolism in addition to embryogenesis [25, 26]. However,
whether Prox1 is directly related to lipid metabolism is
currently unknown.
Because it has been well known that the prolonged use
of rapamycin may cause unwanted side effects such as
hyperlipidemia [17–21], we employed rapamycin to
induce the up-regulation of triglycerides in HepG2 cells
and investigated the effect of rapamycin on the expres-
sion of Prox1. Our data clearly show that rapamycin
increased the amount of triglycerides in HepG2 cells but
not cholesterol (Fig. 1b and c), which is similar to a
previous report [14]. Although there have been several
reports indicating the up-regulation of cholesterol by
rapamycin in organ transplant patients [27], we did not
find a significant increase of cholesterol in this study.
We suppose that this discrepancy may arise from the
difference in concentration or treatment time of
rapamycin.
In our data, the down-regulation of Prox1 by rapamy-
cin did not affect the proliferation of HepG2 cells
(Fig. 1a), but a recent report showed that the treatment
of rapamycin in lymphatic endothelial cells of lymphatic
malformations (LM-LEC) diminished cellular prolifera-
tion [28]. This result may be caused by the physiological
difference between hepatocytes and lymphatic endothe-
lial cells. However, the role of Prox1 in cell physiology
such as proliferation should be elucidated by scrutinizing
the relationship between mTOR signaling and Prox1
using other hepatocyte cell lines or primary hepatocytes.
After confirming the up-regulation of triglycerides by
rapamycin, we investigated the effect of rapamycin on
the expression of Prox1. Interestingly, we found for the
first time that rapamycin down-regulates Prox1 protein
but does not affect its transcript (Fig. 2). This novel find-
ing suggests the importance of mTOR signaling in main-
taining the Prox1 protein in hepatocytes, which should
be investigated further.
In order to understand the role of Prox1 in the regula-
tion of triglycerides, we performed knock-down experi-
ments using small-interfering RNAs (siRNAs), which
mimic the effect of rapamycin in down-regulating the
Prox1 protein. Interestingly, the amount of intracellular
triglycerides was increased by the siProx1 alone, which
is comparable with the effect of rapamycin, and was in-
creased most by siProx1 and rapamycin synergistically
(Fig. 3b and c). These data indicate that siProx1 can
down-regulate the expression of Prox1, which is similar
to the effect of rapamycin, and that Prox1 is a direct
participant in the regulation of triglycerides in hepato-
cytes. The results of loss-of-function studies made us
speculate whether the increased amount of intracellular
triglycerides resulting from rapamycin is regulated by the
replenishment of Prox1 through an over-expression
system. As expected, the up-regulation of triglycerides by
rapamycin returned to normal by Prox1 over-expression,
which means that Prox1 is a crucial factor regulating
triglycerides in hepatocytes (Fig. 3e and f). Next, we
verified the effect of rapamycin on hepatocytes by
systemic injections into mouse. After 2 weeks, lipids and
proteins were extracted from mice livers. The results of
the in vivo experiment showed that rapamycin increases
the amount of triglycerides but down-regulates Prox1
expression in mouse liver (Fig. 4), which is comparable to
the data using HepG2 cells.
Overall, we report here that rapamycin increased the
amount of triglycerides and down-regulated the expres-
sion of Prox1 in HepG2 cells as well as in mouse liver.
The knock-down and the over-expression experiments
showed that Prox1 plays a critical role in the regulation
of triglycerides in hepatocytes. From the results of this
study, we conclude that mTOR signaling is important
for maintaining the Prox1 protein responsible for the
regulation of triglycerides in hepatocytes and suggest
that this is one of reasons that triglycerides are up-
regulated by rapamycin treatment. Further investigation
should be performed to understand the relationship
between mTOR signaling and the regulation of triglycer-
ides by Prox1.
Conclusions
In summary, our study suggests that rapamycin increased
the amount of triglycerides and down-regulated Prox1
expression in hepatocytes. This result indicates that
mTOR signaling is important for the maintenance of
triglycerides by maintaining Prox1 expression.
Methods
Cell cultures, transfection and reagents
The HepG2 cell, a human hepatoma cell line, was pur-
chased from the American Type Culture Collection
(Manassas, VA). The cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) with 10 % fetal bovine
serum (FBS), 5 % penicillin-streptomycin and 5 % so-
dium pyruvate and grown in an atmosphere containing
5 % CO2 at 37 °C. HepG2 cells were incubated with or
without 10nM rapamycin (LC laboratories, MA) in low
serum media (1 % FBS). HepG2 cells were transfected
with 20nM of small interfering RNA (siRNA) against
human Prox1 (5′-GCAAAGAUGUUGAUCCUUCTT-
3′, 5′-GAAGGAUCAACAUCUUUGCTT-3′) for knock-
down experiment or an overexpression system (1 μg
DNA) of Prox1 (human Prox1 coding sequence in
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pcDNA3, kindly provided by Prof. Y-K Hong, University
of Southern California) for expressional compensation
using Lipofector-2000 (Aptabio, Korea). 20 μg/ml of
cycloheximide (CHX, Sigma-Aldrich, MO) was used to
chase the stability of Prox1 protein. After incubation for
12 h with or without rapamycin, HepG2 cells were
treated with cycloheximide from 12 min to 6 h and lysed
for western blot analysis.
Cell proliferation assay
The cell proliferation assay was performed using a Pre-
mixed WST-1 Cell Proliferation Assay kit (TaKaRa,
Japan), as described previously [29]. In brief, HepG2
cells (2 × 104 cells/well) were seeded in 24-well plates
(SPL Inc., Korea) and cultured overnight. Media were
then replaced with fresh media (1 % FBS) containing
rapamycin. Cells were then allowed to grow for 48 h.
WST-1 reagent was added to each well and cells were
incubated for an additional 4 h. Optical absorbance was
subsequently measured at a wavelength of 450 nm using
a microplate reader (Molecular Devices, CA) and the cell
proliferation count was estimated based on a standard
curve that was prepared in parallel.
Thin layer chromatography (TLC) analysis
Total lipids were extracted from cells (1 × 106) or liver
tissues (50 mg) using the chloroform:methanol (1:2 v/v)
extraction method reported by Bligh and Dyer [30].
Triglycerides and cholesterol were separated using a
TLC silica gel 60 plate (Merck, Germany) in a horizontal
TLC chamber with an 9 cm separation length with a
solution of chloroform:methanol:water (60:30:5 v/v/v).
An additional separation from the origin to an 18-cm
separation length was achieved with a hexane:diethyl
ether:acetic acid (80:20:1.5 v/v/v) solution. TLC plates
were visualized by spraying with H2SO4, followed by
heating at 130 °C for 30 min. Acquired images were
processed and analyzed using the Image J program.
Reverse transcription-polymerase chain reaction (RT-PCR)
The expression of Prox1 transcripts were analyzed by
semi-quantitative RT-PCR with human Prox1-specific
primers (sense: 5′-GCAAGTTGTGGACACTGTGGT-3′,
anti-sense: 5′-GGCAGACTGGTCAGAGGAGTT-3′) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-spe-
cific primers (sense: 5′-AGAAGGCTGGGGCTCATTTG-
3′, anti-sense: 5′-AGGGGCCATCCACAGTCTTC-3′) to
achieve equal amounts of cDNA templates. Total RNA
was isolated from HepG2 cells using TRIzol reagent (Life
Technology, CA) and reverse-transcribed using M-MLV
reverse transcriptase (Enzynomics, Korea) and 15 mer
oligo-dT (Promega, WI). Using cDNA as a template, PCR
was performed using the following protocols: (1) 94 °C for
5 min; (2) 26 cycles at 94 °C for 30 s, 55 °C for 30 s, and
72 °C for 1 min; and then (3) 72 °C for 10 min before cool-
ing to 4 °C. Ten microliters of PCR products were loaded
on a 1.5 % agarose gel containing ethidium bromide and
visualized by ultraviolet irradiation. Quantitative real-time
PCR analysis was performed using QuantiSpeed SYBR
Green kit (PhileKorea, Korea) as follows: 50 °C for 10 min,
95 °C for 2 min, and 40 cycles of 95 °C for 10 s, and 55 °C
for 30 s.
Protein extraction and Western blot analysis
Cell lysates were prepared using RIPA buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1 % Nonidet P-40,
0.1 % sodium dodecyl sulfate [SDS] and 0.5 % sodium
deoxycholate) containing protease and phosphatase in-
hibitors (Sigma-Aldrich). Samples were quantified using
the Bradford Protein Assay kit (Pierce Biotechnology, IL)
according to the manufacturer’s instructions. Then 20–
30 μg of proteins were separated on 10 % SDS polyacryl-
amide gel electrophoresis and transferred to polyvinyli-
dene difluoride membranes (PVDF; GE Healthcare, UK).
Western blots were performed with anti-Prox1 antibody
(rabbit polyclonal, kindly provided by Prof. Y-K Hong,
University of Southern California), anti-phospho-mTOR
antibody (sc-101738, Santa Cruz Biotechnology, CA),
anti-β-actin antibody (sc-47778, Santa Cruz Biotechnology),
appropriate secondary antibodies and an enhanced chemi-
luminescence detection reagent (Amersham Pharmacia
Biotech, NJ).
Rapamycin injection into mouse and sample preparation
Eight-week-old BALB/c mice (all male, n = 5/group)
were purchased from RaonBio (Korea) and daily injected
intraperitoneally with rapamycin (4 mg/kg) or vehicle
(5 % polyethylene glycol 400 [Sigma-Aldrich] and 5 %
Tween 80 [Sigma-Aldrich]) as described previously [31].
After 2 weeks, mice were sacrificed and total proteins or
lipids were extracted from mouse liver. The same weight
of liver tissue was lysed using RIPA buffer containing pro-
tease/phosphatase inhibitors (Sigma-Aldrich) and 50 μg of
total protein was used for western blot analysis. For TLC
analysis, total lipids were extracted from 50 mg of liver
tissue using chloroform:methanol (1:2 v/v) solution. All
surgical and experimental procedures were performed
according to the guidelines of the Animal Care and Use
Review Committee of Hoseo University, Korea.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5.0 (GraphPad Software Inc., La Jolla, CA). Results were
expressed as mean ± standard error of three independent
experiments. One-way analysis of variance and Tukey’s
test were used to detect differences, with P < 0.05 and
P < 0.01 considered significant.
Kwon et al. Lipids in Health and Disease  (2016) 15:41 Page 7 of 8
Abbreviations
mTOR: mammalian target of rapamycin; Prox1: prospero-related homeobox 1;
RT-PCR: reverse transcription-polymerase chain reaction; siRNAs: small-
interfering RNAs; TLC: thin layer chromatography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
The manuscript was written by IC and was revised by YH, CA and JS. SK, JJ,
SBK conducted data collection and analysis. This study was designed by IC,
JS and SK. The final manuscript was read and approved by all authors.
Acknowledgments
This research was supported by the Academic Research fund of Hoseo
University in 2012 (2012-0335).
Author details
1Department of Pharmaceutical Engineering, Hoseo University, Asan 336-795,
Republic of Korea. 2Department of Surgery, Norris Comprehensive Cancer
Center, Keck School of Medicine, University of Southern California, Los
Angeles, CA, USA. 3Transplantation Research Institute, Seoul National
University, Seoul, Republic of Korea. 4Department of Life Science, Dongguk
University, Goyang 410-820, Republic of Korea.
Received: 27 August 2015 Accepted: 23 February 2016
References
1. Wigle JT, Oliver G. Prox1 function is required for the development of the
murine lymphatic system. Cell. 1999;98:769–78.
2. Dudas J, Elmaouhoub A, Mansuroglu T, Batusic D, Tron K, Saile B, et al.
Prospero-related homeobox 1 (Prox1) is a stable hepatocyte marker during
liver development, injury and regeneration, and is absent from “oval cells”.
Histochem Cell Biol. 2006;126:549–62.
3. Lee S, Choi I, Hong Y-K. Heterogeneity and plasticity of lymphatic
endothelial cells. Semin Thromb Hemost. 2010;36:352–62.
4. Harvey NL, Srinivasan RS, Dillard ME, Johnson NC, Witte MH, Boyd K, et al.
Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause
adult-onset obesity. Nat Genet. 2005;37:1072–81.
5. Qin J, Gao DM, Jiang QF, Zhou Q, Kong YY, Wang Y, et al. Prospero-related
homeobox (Prox1) is a corepressor of human liver receptor homolog-1 and
suppresses the transcription of the cholesterol 7-alpha-hydroxylase gene.
Mol Endocrinol. 2004;18:2424–39.
6. Song KH, Li T, Chiang JY. A prospero-related homeodomain protein is a
novel co-regulator of hepatocyte nuclear factor 4alpha that regulates the
cholesterol 7alpha-hydroxylase gene. J Biol Chem. 2006;281:10081–8.
7. Lee S, Kang J, Yoo J, Ganesan SK, Cook SC, Aguilar B, et al. Prox1 physically
and functionally interacts with COUP-TFII to specify lymphatic endothelial
cell fate. Blood. 2009;113:1856–9.
8. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci.
2009;122:3589–94.
9. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new
era in interventional cardiology. Heart. 2002;87:305–7.
10. Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nat Rev Mol
Cell Biol. 2003;4:117–26.
11. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new
molecular target for breast cancer. Clin Breast Cancer. 2003;4:126–37.
12. Xu X, Sakon M, Nagano H, Hiraoka N, Yamamoto H, Hayashi N, et al. Akt2
expression correlates with prognosis of human hepatocellular carcinoma.
Oncol Rep. 2004;11:25–32.
13. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of
action of some commonly used protein kinase inhibitors. Biochem J.
2000;351:95–105.
14. Aggarwal D, Fernandez ML, Soliman GA. Rapamycin, an mTOR inhibitor,
disrupts triglyceride metabolism in guinea pigs. Metabolism. 2006;55:794–
802.
15. Kahan BD. The limitations of calcineurin and mTOR inhibitors: new
directions for immunosuppressive strategies. Transplant Proc. 2002;34:130–3.
16. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction
pathway as a target for cancer therapy. Oncogene. 2000;19:6680–6.
17. Dutcher JP. Mammalian target of rapamycin (mTOR) inhibitors. Curr Oncol
Rep. 2004;6:111–5.
18. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase
I study in quiescent cyclosporine-prednisone–treated renal transplant
patients. Kidney Int. 1996;49:209–16.
19. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an
analysis using the Framingham risk model. Am J Transplant. 2002;2:551–9.
20. Mathe D, Adam R, Malmendier C, Gigou M, Lontie JF, Dubois D, et al.
Prevalence of dyslipidemia in liver transplant recipients. Transplantation.
1992;54:167–70.
21. Kahan BD, Yakupoghlu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, et al.
Low incidence of malignancy among sirolimus/cyclosporine-treated renal
transplant recipients. Transplantation. 2005;80:749–58.
22. Soliman GA. The integral role of mTOR in lipid metabolism. Cell Cycle.
2011;10:861–2.
23. Houde VP, Brûlé S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y,
et al. Chronic rapamycin treatment causes glucose intolerance and
hyperlipidemia by upregulating hepatic gluconeogenesis and impairing
lipid deposition in adipose tissue. Diabetes. 2010;59:1338–48.
24. Choi I, Lee S, Hong Y-K. The new era of the lymphatic system: no longer
secondary to the blood vascular system. Cold Spring Harb Perspect Med.
2012;2:a006445.
25. Charest-Marcotte A, Dufour CR, Wilson BJ, Tremblay AM, Eichner LJ, Arlow DH,
et al. The homeobox protein Prox1 is a negative modulator of ERRα/PGC-1α
bioenergetic functions. Genes Dev. 2010;24:537–42.
26. Dufour CR, Levasseur MP, Pham NH, Eichner LJ, Wilson BJ, Charest-Marcotte
A, et al. Genomic convergence among ERRα, PROX1, and BMAL1 in the
control of metabolic clock outputs. PLoS Genet. 2011;7:e1002143.
27. Holdaas H, Potena L, Saliba F. mTOR inhibitors and dyslipidemia in
transplant recipients: a cause for concern? Transplant Rev. 2015;29:93–102.
28. Boscolo E, Coma S, Luks VL, Greene AK, Klaqsbrun M, Warman ML, et al. AKT
hyper-phosphorylation associated with PI3K mutations in lymphatic
endothelial cells from a patient with lymphatic malformation. Angiogenesis.
2015;18:151–62.
29. Choi I, Lee YS, Chung HK, Choi D, Ecoiffier T, Lee HN, et al. Interleukin-8
reduces post-surgical lymphedema formation by promoting lymphatic
vessel regeneration. Angiogenesis. 2013;16:29–44.
30. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification.
Can J Biochem Physiol. 1959;37:911–7.
31. Hartman AL, Santos P, Dolce A, Hardwick JM. The mTOR inhibitor rapamycin
has limited acute anticonvulsant effects in mice. PLoS One. 2012;7:e45156.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kwon et al. Lipids in Health and Disease  (2016) 15:41 Page 8 of 8
